Tenaya Therapeutics (TNYA) Non Operating Income (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Non Operating Income of $793000.0 for Q1 2026, up 17.66% year-over-year from $674000.0 in Q1 2025, and up 32.17% quarter-over-quarter from $600000.0 in Q4 2025.
Tenaya Therapeutics (TNYA) Non Operating Income (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Non Operating Income history runs 7 years deep, the most recent figure standing at $793000.0 for Q1 2026.
- In Q1 2026, Non Operating Income rose 17.66% year-over-year to $793000.0; the TTM figure through Mar 2026 stood at $2.9 million (down 27.94% YoY), while the FY2025 annual figure was $2.7 million, down 43.27% from the prior year.
- Non Operating Income for Q1 2026 stood at $793000.0, up from $600000.0 in the prior quarter.
- The five-year high for Non Operating Income was $2.0 million in Q1 2023, with the low at $98000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $816000.0 (2024), against an average of $1.0 million.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income soared 7853.85% in 2022, then sank 56.06% in 2025.
- Tenaya Therapeutics' Non Operating Income stood at $1.0 million in 2022, then soared by 46.13% to $1.5 million in 2023, then sank by 46.0% to $816000.0 in 2024, then decreased by 26.47% to $600000.0 in 2025, then soared by 32.17% to $793000.0 in 2026.
- Business Quant data shows TNYA's Non Operating Income at $793000.0 in Q1 2026, $600000.0 in Q4 2025, and $661000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Tenaya Therapeutics | 151.50 Mn | 151.50 Mn | - | 695,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 695,000.00 |
| Mar 31, 2026 | 793,000.00 |
| Dec 31, 2025 | 600,000.00 |
| Sep 30, 2025 | 661,000.00 |
| Jun 30, 2025 | 799,000.00 |
| Mar 31, 2025 | 674,000.00 |
| Dec 31, 2024 | 816,000.00 |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Mar 31, 2024 | 1.53 Mn |
| Dec 31, 2023 | 1.51 Mn |
| Sep 30, 2023 | 1.78 Mn |
| Jun 30, 2023 | 1.84 Mn |
| Mar 31, 2023 | 1.99 Mn |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 602,000.00 |
| Jun 30, 2022 | 222,000.00 |
| Mar 31, 2022 | 98,000.00 |
| Dec 31, 2021 | 13,000.00 |
| Sep 30, 2021 | 38,000.00 |